Inventiva S.a. key statistics and ratios
In fiscal 2025, Inventiva S.a. had an operating margin of -3145.5% and a current ratio of 3.16. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.
Financial ratios
| Fiscal year | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating margin | <−999% | −433.2% | <−999% | <−999% | −468.9% | −587.7% | <−999% | <−999% |
| Net margin | <−999% | −431.8% | <−999% | <−999% | −445.6% | −631.8% | <−999% | <−999% |
| Return on equity | −55.3% | −57.8% | −42.0% | −49.6% | −76.6% | — | — | — |
| Return on assets | −42.7% | −43.5% | −32.8% | −38.1% | −43.6% | −118.8% | −199.2% | −192.5% |
| Asset turnover | 0.04 | 0.10 | 0.00 | 0.03 | 0.10 | 0.19 | 0.10 | 0.02 |
| Current ratio | 4.75 | 3.53 | 9.56 | 5.06 | 3.47 | 0.96 | 0.92 | 3.16 |
| Debt to equity | 0.4% | 0.3% | 9.0% | 11.4% | 97.6% | — | — | — |
| Interest cover (operating income ÷ interest) | n/m | n/m | n/m | n/m | n/m | n/m | n/m | n/m |
| R&D as % of revenue | 993.4% | 482.9% | >999% | >999% | 496.5% | 629.5% | 988.0% | >999% |
Financial health
- Short-term assets cover short-term liabilities $287m of assets due within a year against $91m of liabilities due within a year.
- Short-term assets cover long-term liabilities $287m short-term assets against $235m of longer-dated liabilities.
- More cash than debt Cash or debt not separately reported. Not assessable.
- Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
- Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
- A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
- Operating profit covers interest at least five times over Operating income of −$159m against $38m of interest.
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Compare with peers
- Adlai Nortye Group Ltd. statistics
- Immuron Ltd statistics
- Rani Therapeutics Holdings, Inc. statistics
- Bolt Biotherapeutics, Inc. statistics
- Entrada Therapeutics, Inc. statistics
Head to head: ANL vs IVAIMRN vs IVAIVA vs RANI
More: Biotechnology stocks compared, Health Care sector, rankings of US companies